STADA has acquired the rights to Nizoral Cream in Vietnam, the Philippines, and Thailand and trademark rights in Hong Kong, Australia, Indonesia, Malaysia, New Zealand, and Singapore. This acquisition continues STADA’s successful acquisition of Nizoral Brands in several EMEA markets. The acquisition strengthens STADA’s role as a partner of choice in consumer healthcare in the Asia-Pacific region. The product, which contains ketoconazole, is used for treating fungal skin infections. STADA EVP Emerging Markets Stephane Jacqmin expressed satisfaction with the acquisition.
Under the terms of the agreement, STADA acquires the existing distribution and Nizoral Cream business in the Philippines, Vietnam, and Thailand markets and the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand, and Singapore.
This transaction extends a previous asset deal to the APAC region. In 2018, STADA successfully acquired the Nizoral brand in key EMEA markets.
STADA EVP for Emerging Markets Stephane Jacqmin said, “We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare”.
